2 results
Approved WMOCompleted
To assess the effect of switching CML patients, who have been treated with imatinib *2 years and who have stable detectable molecular residual disease above 0.01% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of…
Approved WMOCompleted
In a pilot study patients scheduled for a regular implantation of a (or undergoing an upgrade to a) CRT-device will also be implanted with a heart monitor in the pulmonary artery. This implantable heart monitor (IHM) will collect data during…